Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer

Journal of the National Cancer Institute

Volumn 91, Issue 10, 1999, Pages 882-885

  Tang, Nelson L S ^a   Pang, Chi Pui ^a   Yeo, Winnie ^a   Choy, Kwong Wai ^a   Lam, P Kuen ^a   Suen, Michael ^a   Law, Lap K ^a   King, Walter W K ^a   Johnson, Philip ^a   Hjelm, Magnus ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CHINESE; DNA REPAIR; GENE MUTATION; HIGH RISK POPULATION; PREVALENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033583762     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.10.882     Document Type: Article

References (28)

1. Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium [letter]. Lancet 1994;344:761.
2. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2 [editorial]. Am J Hum Genet 1997;60:1013-20.
3. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416-21.
4. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-50.
5. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266: 120-2.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
7. Larson JS, Tonkinson JL, Lai MT. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 1997;57:3351-5.
8. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997;389:187-90.
9. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.
10. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8-18.
11. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059-67.
12. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
13. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Linkage analysis of BRCA1 in Japanese breast cancer families. Jpn J Cancer Res 1994;85:1233-9.
14. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995;55:3521-4.
15. Katagiri T, Emi M, Ito I, Kobayashi K, Yoshimoto M, Iwase T, et al. Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum Mutat 1996;7:334-9.
16. Hong Kong Cancer Registry. Cancer incidence and mortality in Hong Kong 1993-94. Hong Kong: Hong Kong Hospital Authority, 1998.
17. Yeo M, Kwan WH, Lee WY, Leung TWT, Teo PML, King W, et al. Familial breast cancer in Hong Kong Chinese. Hong Kong Med J 1996;2:68-71.
18. Clayton EW, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Kahn MJ, et al. Informed consent for genetic research on stored tissue samples. JAMA 1995;274: 1786-92.
19. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994; 8:387-91.
20. Schehl CM, Ostrander GK. Identification of BRCA1 germline mutation, 797de1AA, in a Japanese breast-ovarian cancer patient [letter]. J Natl Cancer Inst 1997;89: 1547-8.
21. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58:1588-92.
22. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-10.
23. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
24. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80: 435-41.
25. Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10: 208-12.
26. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
27. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 1996;5: 835-42.
28. Sobin LH, Wittekind C. TNM classification of malignant tumours. New York (NY): John Wiley & Sons; 1997.